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ABSTRACT: Background. Little is known about the determinants of
postradiation neck spasms in patients with head and neck cancer.
Methods. Patients with head and neck cancer treated with radiation
therapy (RT) from 2004 to 2010 who experienced neck spasms
were reviewed. Radiation doses were generated for their
sternocleidomastoid (SCM) muscles bilaterally. Unaffected SCMs were
used as controls.
Results. Thirty-four patients reported neck spasms. Thirty had received
definitive chemoradiation, and 4 had RT alone. Seven also had an
ipsilateral neck dissection. Median time to onset was 23 months (range,
6–67 months). There were significantly higher radiation doses to the
affected SCMs with a median of the mean dose to the affected and
unaffected SCM of 62.3 Gy (range, 29–71 Gy) and 53.7 Gy (range,
27–65 Gy), respectively (p < .0001). Other dosimetric variables were
also statistically significant but were highly correlated with the mean
SCM dose. Neck dissection did not affect our results.
Conclusion. Neck spasms after chemotherapy intensity-modulated
radiation therapy (IMRT) shows a strong dose–response relationship.
VC 2013 Wiley Periodicals, Inc. Head Neck 36: 176–180, 2014
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INTRODUCTION
As tumor control rates and treatment outcomes improve,
there has been increasing interest in minimizing treat-
ment-related toxicity for patients with head and neck can-
cer. Although it is common to have an assortment of
vague, brief, uncomfortable sensations in the area of pre-
vious treatment, we have seen a consistent trend of neck
muscle spasm symptoms late after therapy, described as a
‘‘Charlie horse–like’’ sensation by our patients. Very lit-
tle has been published in the medical literature about this
late effect. In this study, we report the clinical details of
this complication and its dosimetric correlates.
MATERIALS AND METHODS
As part of our routine clinical practice, we identified
and tracked all patients complaining of neck spasms after
radiation therapy at the University of Michigan between
2004 and 2010. After these complaints were first noticed,
we have documented the frequency, quality, and duration
of symptoms, as well as any triggers, alleviating or aggra-
vating factors, and treatments received for this complica-
tion. Routine clinical follow-up after therapy consists of
visits every 2 months during the first 2 years, every 3
months in the third year, and every 6 months thereafter
through 5 years. We have now retrospectively reviewed
these records to collect this data, as well as clinical and
treatment variables. This retrospective study was
approved by the Institutional Review Board of the Uni-
versity of Michigan with a waiver of informed consent.
The sternocleidomastoid (SCM) muscles for these
patients were contoured using our in-house treatment
planning system, UMPlan. The entire length of the SCM
muscles was contoured from its origin at the manubrium
and clavicle to its insertion at the mastoid and occipital
bone bilaterally. Dose–volume histograms were calculated
separately for the SCM on each side of the neck. For
each patient, an ‘‘affected’’ and ‘‘unaffected’’ side of the
neck was determined from the clinical follow-up notes.
Statistical analysis was performed using a t test com-
paring dosimetric variables for the affected and unaf-
fected SCM muscles in each patient. For patients with
unilateral neck spasms, the unaffected side was used as
an internal control. For patients with bilateral neck
spasms, both sides were included in the analysis as
affected SCM muscles. Pearson’s correlation coefficient
was used to evaluate the association between dosimetric
factors and occurrence of spasm.
In addition to the above analysis, a second comparison
was performed in an attempt to elucidate clinical factors
related to the development of neck spasms. Twelve of the
patients identified with neck spasms (as described above)
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were treated on a prospective clinical protocol (n ¼ 72)
for patients with stage III to IV oropharyngeal cancer.
These patients received definitive chemoradiation with
weekly carboplatin (area under the curve ¼ 1) and
paclitaxel (30 mg/m2). Radiation was delivered using
intensity-modulated radiation therapy (IMRT) with a pre-
scription dose of 70 Gy to the primary tumor and involved
lymph nodes, 59 to 63 Gy to high-risk nodal regions and
the anatomic compartments around the gross tumor vol-
umes, and 56 to 59 Gy to low-risk nodal regions. Priority
was given during planning to spare the major salivary
glands, pharyngeal constrictor muscles, larynx (glottis and
supraglottic larynx), and esophagus, to minimize late xero-
stomia and dysphagia. Details of the radiation treatment
planning have been previously published.1
The clinical variables from the 12 protocol patients who
developed neck spasms were compared with the 60 proto-
col patients who did not develop neck spasms. A 1-way
analysis of variance test was used for this comparison.
RESULTS
Thirty-four patients developed posttreatment neck
spasms. Their median age was 58 years (range, 42–71
years). There were 31 men and 3 women. The primary
site of disease was unknown in 4 patients, glottic larynx
in 1 patient, supraglottic larynx in 2 patients, retromolar
trigone in 1 patient, and oropharyngeal in 26 patients (15
patients with tonsil, 10 patients with base of tongue, and
1 patient with a posterior pharyngeal wall cancer). During
this period of time, we treated 221 patients with oropha-
ryngeal cancer (12% developed neck spasms), 28 patients
with unknown primary cancer (14% developed neck
spasms), 33 patients with laryngeal cancer (3% developed
neck spasms), 50 patients with supraglottic cancer (4%
developed neck spasms), and 20 patients with oral cavity
cancer (5% developed neck spasms).
Thirty patients (88%) received definitive concurrent
chemoradiation therapy, 2 patients received definitive
radiation alone, and 2 patients received postoperative
radiation alone. Seven patients underwent neck dissection
on the affected side before the onset of their neck spasms
(3 had surgery preradiation therapy and 4 had surgery
postradiation therapy).
The median follow-up is 51 months (range, 30–90
months) with most patients continuing their follow-up at
our department, at the time of this publication. Twenty-six
patients developed unilateral neck spasms and 8 had bilat-
eral neck symptoms. In all cases of unilateral symptoms,
the affected neck side was ipsilateral to the site of the pri-
mary tumor (in patients with lateralized tumors). The me-
dian time to symptom onset was 23 months (range, 6–67
months). Once symptoms began, the median duration of
symptoms was 24 months (range, 2–48 months) with all
but 6 patients continuing to have symptoms at the time of
their last follow-up.
Patients describe their neck spasms as a ‘‘Charlie
horse–like’’ painful contraction in their neck, typically
pointing to the SCM as the site of spasm. These myoclo-
nus events are brief and last less than 1 minute in all but
1 patient who described events lasting 4 to 5 minutes.
Spasm events were triggered by specific neck positions
and movements such as head turning, yawning, and stren-
uous physical activity such as weight lifting. Spasms are
commonly alleviated by neck stretching or massage. For
most patients, these neck spasms were not painful. How-
ever, 7 patients did require additional intervention
because these spasms were painful and/or distressing.
Two patients were referred for physical therapy, and 6
patients required some form of medication (potassium
supplements in 1 patient, aspirin in 1 patient, benzodiaze-
pines or muscle relaxers in 3 patients, and gabapentin and
tramadol in 1 patient). Only 1 patient reported that neck
spasms necessitated a leave of absence from work (this
patient previously worked as a truck driver and reported
that turning his neck while driving caused him significant
pain). Two additional patients complained that SCM mus-
cle twitching caused them embarrassment at work but did
not interfere with their ability to perform their jobs.
In addition, the severity of the neck spasms waxed and
waned over time with abrupt exacerbations occasionally
occurring long after the end of radiation therapy (RT).
For 1 patient, symptoms were mild until they suddenly
worsened after a strenuous basketball game 24 months af-
ter the completion of his RT. At his last follow-up, he
reported that his symptoms were still continuing at the
increased level of severity.
Physical examination of the neck was unremarkable in
all patients, and no patients had evidence of muscle, skin,
or soft tissue fibrosis or limitation in neck movements.
Dosimetric data compiled from the affected and unaf-
fected SCM muscles is listed in Table 1. The medians of
TABLE 1. Dosimetric data for sternocleidomastoid muscles with and without neck spasms.
SCM without neck spasms, median (range) SCM with neck spasms, median (range) p value
Mean dose 53.7 Gy (27.3–65.4) 62.3 Gy (29.4–71.0) .00001
Max dose to 0.5% volume (D0.5) 65.0 Gy (58.4–74.9) 73.8 Gy (63.0–77.5) <.00001
Max dose to 20% volume (D20) 61.4 Gy (55.6–72.4) 68.7 Gy (60.7–75.3) <.00001
Max dose to 95% volume (D95) 22.2 Gy (0.6–56.7) 48.4 Gy (0.2–60.5) <.00001
Max dose to 0.5 cc (D0.5 cc) 64.8 Gy (58.3–74.5) 73.3 Gy (62.9–77.4) <.00001
Max dose to 1.0 cc (D1 cc) 64.1 Gy (58.0–73.9) 72.6 Gy (62.6–77.3) <.00001
Volume receiving 40 Gy (V40) 86.2% (40.0–100.0) 98.2% (43.3–100) .0002
Volume receiving 50 Gy (V50) 78.9% (31.8–98.7) 94.6% (39.7–99.7) .00002
Volume receiving 60 Gy (V60) 43.5% (0–89.4) 77.5% (28.4–95.8) <.00001
Volume receiving 65 Gy (V65) 0.5% (0–69.1) 46.3% (0–86.9) <.00001
Volume receiving 70 Gy (V70) 0% (0–53.9) 10.1% (0–76.02) .003
Abbreviations: SCM, sternocleidomastoid; max, maximum.
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the mean doses to the SCM for the affected and unaf-
fected muscles were 62.3 Gy (range, 29–71 Gy) and 53.7
Gy (range, 27–65 Gy), respectively (p < .0001). Using
the mean dose for all SCM muscles (58 Gy) as a cutoff
value had a sensitivity of 83%, specificity of 77%, posi-
tive predictive value of 85%, and negative predictive
value of 74% for predicting posttreatment neck spasms.
Other dosimetric variables were also statistically signifi-
cant but were highly correlated with the mean SCM dose
(correlation coefficient 0.76 for all variables listed in
Table 1, except for V70 with a correlation coefficient of
0.57). Cumulative dose volume histograms for all SCM
analyzed are shown in Figure 1.
We also examined the utility of using a mean dose of
56 Gy to the SCM as a cutoff value for predicting neck
spasms because 56 Gy is used as an elective nodal dose
in Radiation Therapy Oncology Group trials. Thirty-one
percent of SCM muscles (8 of 26) without neck spasms
received a mean dose 56 Gy or more compared with 90%
of SCM muscles (38 of 42) with neck spasms. These
results suggest that keeping mean SCM doses below 56
Gy is likely to decrease the incidence of this posttreat-
ment complication.
In order to exclude the effect of neck dissection on the
occurrence of neck spasms and its potential influence on
dose-effect relationships, the same analysis was per-
formed excluding the 7 patients who had undergone a
neck dissection as part of their treatment. These results
are shown in Table 2, demonstrating very similar doses
and statistically significant differences between the SCMs
in the affected and nonaffected neck sides as those found
in the whole population (Table 1) of patients with symp-
toms. During the period of this study, 221 patients with
oropharyngeal cancer were treated. Twenty-eight percent
(62 of 221 patients) underwent neck dissection (only 1
patient underwent neck dissection pretreatment). The rate
of neck dissection among patients with oropharyngeal
cancer that developed neck spasms (19%; 5 of 26
patients) was lower than the rate for patients with oropha-
ryngeal cancer that did not develop neck spasms (29%;
57 of 195 patients). This trend is difficult to interpret as
our general rate of posttreatment neck dissection has
declined with time as part of our institutional practice.
In order to examine which clinical variables may be
related to the development of neck spasms, we analyzed
the dataset of 72 patients with oropharyngeal cancer
treated with definitive chemo-IMRT as part of a prospec-
tive study at our institution. Of these 72 patients, 12
patients had neck spasms and were included in the analy-
sis in this article. Comparison of these 12 patients to the
other 60 patients who were treated in an identical manner
but did not develop neck spasms (Table 3), showed that
the patients with neck spasms had significantly lower T
stage and were more likely to be nonsmokers.
In order to assess whether better prognosis patients
lived longer and were therefore more likely to develop
neck spasms, we also examined the survival data for this
72 patient cohort of patients with oropharyngeal cancer.
All 12 patients in this cohort that developed neck spasms
were alive and continuing to follow-up with us (median
follow-up 5.8 years; range, 4.6–8.9 years). The 60
patients in this group that did not develop neck spasms
were followed for a median of 4.9 years (range, 6–67
months) with 14 deaths in this group. Only 4 patients in
FIGURE 1. Higher overall radiation dose to sternocleidomastoid
muscles affected by posttreatment neck spasms. Cumulative
dose volume histograms for sternocleidomastoid muscles on the
side of the neck affected (dark red) and unaffected (light blue) by
posttreatment neck spasms. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
TABLE 2. Dosimetric data for sternocleidomastoid muscles with and without neck spasms, excluding patients undergoing neck dissection.
SCM without neck spasms, median (range) SCM with neck spasms, median (range) p value
Mean dose 53.2 Gy (27.8–65.4) 60.9 Gy (29.4–71.0) .00009
Max dose to 0.5% volume (D0.5) 66.4 Gy (62.4–74.9) 72.7 Gy (63.0–77.5) <.00001
Max dose to 20% volume (D20) 63.1 Gy (59.7–72.4) 68.2 Gy (60.7–75.3) <.00001
Max dose to 95% volume (D95) 27.0 Gy (0.6–56.7) 43.4 Gy (0.2–60.5) .0003
Max dose to 0.5 cc (D0.5 cc) 66.1 Gy (62.3–74.5) 72.3 Gy (62.9–77.4) <.00001
Max dose to 1.0 cc (D1 cc) 65.6 Gy (61.9–73.9) 71.9 Gy (62.6–77.3) <.00001
Volume receiving 40 Gy (V40) 84.1% (40.0–100.0) 94.6% (43.3–100) .004
Volume receiving 50 Gy (V50) 77.6% (35.4–98.7) 90.0% (39.7–99.5) .001
Volume receiving 60 Gy (V60) 46.5% (16.5–89.4) 72.1% (28.4–95.8) .00001
Volume receiving 65 Gy (V65) 11.6% (0–69.1) 43.2% (0–86.9) <.00001
Volume receiving 70 Gy (V70) 4.4% (0–53.9) 17.1% (0–76.02) .01
Abbreviations: SCM, sternocleidomastoid; max, maximum.
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the ‘‘no spasm group’ lived less than 23 months, which is
the median time to onset of neck spasms for all patients,
suggesting that nearly all patients in both groups lived
long enough to be at risk for developing neck spasms.
DISCUSSION
This series describes myoclonus episodes centered on
the SCM starting at a median of 23 months after the com-
pletion of therapy. The rate of these episodes has been
12% to 14% in patients with oropharyngeal or unknown
primary tumors receiving comprehensive chemoradiation
at our institution. To our knowledge, only 2 case series
have been previously published documenting this phe-
nomenon.2,3 Van Daele et al2 reported a series of 9
patients treated with RT to the head and neck region (8
patients with head and neck cancer and 1 patient with
Merkel cell carcinoma involving the cheek), and the
group at Memorial Sloan-Kettering Cancer Center have
presented a cohort of 18 patients with this
complication.3–6 In both of these series, botulinum A
toxin has been successfully used to treat pain in refractory
patients.
Our series is unique in assessing the prevalence of
myoclonus among patients receiving comprehensive
chemo-RT, its course over time, and its relationships with
the doses delivered to the SCM. In our group, only 7 of
33 patients required any intervention specifically for neck
spasms with only 1 patient reporting that spasms inter-
fered with his daily life and required narcotic medication.
This complication can continue on for many years and
can change unpredictably over time with only 6 of our 33
patients reporting resolution of their symptoms at their
last follow-up despite a median follow-up of 4.25 years.
Fortunately for most patients, the symptoms were mild,
brief, and do not require treatment.
The mechanism of postradiation muscle injury is an
ongoing area of investigation, but given its late onset, it
is likely related to chronic vascular injury or direct myo-
cyte injury. Animal studies using large single doses of
radiation have shown delayed fibrosis and vascular
lesions characteristic of radiation injury with the resulting
loss of large numbers of muscle fibers years after radia-
tion exposure (50% loss of muscle fibers with a single
dose of 21 Gy).7 Animal studies have also shown changes
in muscle metabolism with the increased deposition of
extracellular collagen potentially disrupting myocyte orga-
nization and communication, as well as elevated levels of
transforming growth factor-beta in myocytes, inflamma-
tory cells, and extracellular matrix up to a year after RT
suggesting a role for cytokines in signaling posttreatment
fibrosis.7 Examination of human tissue from patients
experiencing radiation-induced myopathy also demon-
strates muscle atrophy, fibrosis, and radiation-induced
vascular injury.8 Doses above 63 Gy in standard fractio-
nation have been shown to cause muscle edema,
decreased muscle strength, and decreased range of motion
in patients treated for soft tissue sarcomas of the
extremities.9
In this article, we report an 83% sensitivity and 77%
specificity for a cutoff value of 58 Gy for mean dose in
predicting posttreatment neck spasms. This value was
chosen because it was the average of the mean dose for
all SCM muscles in this patient group. However, many
dosimetric factors were highly correlated with the devel-
opment of posttreatment neck spasms. As these factors
were also highly correlated with the mean SCM doses,
the mean dose remains as the easiest parameter to use.
Further studies would be needed to validate this finding
and find the best cutoff dosimetric value.
In the patients with unilateral symptoms, the affected
side of the neck was ipsilateral to the site of the primary
TABLE 3. Comparison of patients with oropharyngeal cancer treated on the same prospective protocol (n5 72).
Patients without neck spasm Patients with neck spasm p value
Age Median, 55 y Median, 52 y NS
Sex 6 females (10%) 2 females (17%) NS
54 males (90%) 10 males (83%)
T classification T1: 7 patients (12%) T1: 2 patients (17%) .02
T2: 20 patients (33%) T2: 9 patients (75%)
T3: 15 patients (25%) T3: 1 patient (8%)
T4: 18 patients (30%) T4: 0 patients
N classification N0: 5 patients (8%) N0: 0 patients NS
N1: 4 patients (7%) N1: 2 patients (17%)
N2a: 7 patients (12%) N2a: 1 patient (8.3%)
N2b: 26 patients (43%) N2b: 7 patients (58%)
N2c: 13 patients (22%) N2c: 1 patient (8.3%)
N3: 5 patients (8%) N3: 1 patients (8.3 %)
AJCC stage Stage 3: 6 patients (10%) Stage 3: 2 patients (17%) NS
Stage 4a: 49 patients (82%) Stage 4a: 9 patients (75%)
Stage 4b: 5 patients (8%) Stage 4b: 1 patient (8%)
Disease site Tonsil: 28 patients (47%) Tonsil: 6 patients (50%) NS
Base of tongue: 32 patients (53%) Base of tongue: 6 patients (50%)
Smoking status Current: 16 patients (27%) Current: 0 patients .005
Former: 27 patients (45%) Former: 3 patients (25%)
Never: 17 patients (28%) Never: 9 patients (75%)
Abbreviations: NS, not significant; AJCC, American Joint Committee on Cancer.
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tumor, where nodal disease was more prevalent and,
therefore, the prescribed radiation doses were higher. A
substantial reduction of the doses to the SCMs is usually
not attainable when gross nodal disease is treated. How-
ever, if studies of reduced radiation doses for patients
with human papillomavirus-related oropharyngeal cancers
are successful, reducing the doses to the involved neck in
such patients in the future will be expected to reduce the
rate of late neck spasms, as demonstrated in the dosimet-
ric comparisons in this article.
The only clinical factors that were imbalanced between
patients with oropharyngeal cancer that did and did not
develop neck spasms after treatment on a prospective pro-
tocol with concurrent treatment were lower T classifica-
tion and a higher rate of nonsmokers among patients who
developed neck spasms. This could be explained by a
higher rate of neck spasms among patients with human
papillomavirus–related oropharyngeal cancers because
these patients tend to be nonsmokers and have an earlier
tumor stage with more-advanced nodal disease.
The strength of this study is its size. To the best of our
knowledge, this is the largest series of patients with post-
treatment neck spasms in the published literature and the
first to report information regarding the prevalence of this
complication and its radiation dose-response relationship.
The limitations of this study are the major limitations of
any retrospective study. We are not able to control for
confounders in treatment selection or disparities in post-
treatment follow-up. In addition, our patients did not
undergo objective studies such as electromyography or
MRI to further clarify the underlying pathophysiology of
this complication. We believe that this data is interesting
and hypothesis generating; however, validation in another
patient cohort is warranted.
In conclusion, our data suggests a strong dose response
relationship between posttreatment neck spasms and radi-
ation doses to the SCM. Although this complication can
occur late and last for many years, fortunately, these
symptoms were mild for most patients.
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